|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-5-28
|
|
pubmed:abstractText |
Panitumumab is a fully human monoclonal antibody directed against the epidermal growth factor receptor and is indicated for patients with metastatic colorectal cancer (mCRC) who have experienced disease progression after standard chemotherapy. We conducted this phase II study to assess the ability of panitumumab to be administered with first-line irinotecan-containing regimens in patients with mCRC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1533-0028
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
427-32
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17531105-Adenocarcinoma,
pubmed-meshheading:17531105-Adult,
pubmed-meshheading:17531105-Aged,
pubmed-meshheading:17531105-Antibodies, Monoclonal,
pubmed-meshheading:17531105-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17531105-Camptothecin,
pubmed-meshheading:17531105-Colorectal Neoplasms,
pubmed-meshheading:17531105-Female,
pubmed-meshheading:17531105-Fluorouracil,
pubmed-meshheading:17531105-Humans,
pubmed-meshheading:17531105-Leucovorin,
pubmed-meshheading:17531105-Male,
pubmed-meshheading:17531105-Middle Aged,
pubmed-meshheading:17531105-Neoplasm Metastasis,
pubmed-meshheading:17531105-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17531105-Vitamin B Complex
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
|
|
pubmed:affiliation |
Vanderbilt University Medical Center, Nashville, TN 37232-6307, USA. jordan.berlin@vanderbilt.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
